Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3520 ARTÍCULOS , VIENDO DEL 2191 AL 2205

Protocol for a home-based integrated physical therapy program to reduce falls and improve mobility in people with Parkinson's disease

Morris ME, Martin C, McGinley JL, Huxham FE, Menz HB, Taylor NF, Danoudis M, Watts JJ, Soh SE, Evans AH, Horne M, Kempster P.

BMC Neurol. 2012 Jul 16;12:54. doi: 10.1186/1471-2377-12-54.

Efficacy and safety of extended- versus immediate-release pramipexole in Japanese patients with advanced and L-dopa-undertreated Parkinson disease: a double-blind, randomized trial

Mizuno Y, Yamamoto M, Kuno S, Hasegawa K, Hattori N, Kagimura T, Sarashina A, Rascol O, Schapira AH, Barone P, Hauser RA, Poewe W; Pramipexole ER Study Group.

Clin Neuropharmacol. 2012 Jul-Aug;35(4):174-81. doi: 10.1097/WNF.0b013e31825f77b9.

The MAPT H1 haplotype is associated with tangle-predominant dementia

Santa-Maria I, Haggiagi A, Liu X, Wasserscheid J, Nelson PT, Dewar K, Clark LN, Crary JF.

Acta Neuropathol. 2012 Nov;124(5):693-704. doi: 10.1007/s00401-012-1017-1. Epub 2012 Jul 17.

Health-related quality of life and strain in caregivers of Australians with Parkinson's disease: an observational study

Kelly DH, McGinley JL, Huxham FE, Menz HB, Watts JJ, Iansek R, Murphy AT, Danoudis M, Adair B, Morris ME.

BMC Neurol. 2012 Jul 17;12:57. doi: 10.1186/1471-2377-12-57.

The dynamics of neurological disease: integrating computational, experimental and clinical neuroscience

Coombes S, Terry JR.

Eur J Neurosci. 2012 Jul;36(2):2118-20. doi: 10.1111/j.1460-9568.2012.08185.x.

A systematic review of catechol-0-methyltransferase inhibitors: efficacy and safety in clinical practice

Marsala SZ, Gioulis M, Ceravolo R, Tinazzi M.

Clin Neuropharmacol. 2012 Jul-Aug;35(4):185-90. doi: 10.1097/WNF.0b013e31825c034a.

Clinical trials of dementia with Lewy bodies and Parkinson's disease dementia

Aarsland D, Ballard C, Rongve A, Broadstock M, Svenningsson P.

Curr Neurol Neurosci Rep. 2012 Oct;12(5):492-501. doi: 10.1007/s11910-012-0290-7.

Inflammation in Parkinson's disease: cause or consequence?

Appel SH.

Mov Disord. 2012 Aug;27(9):1075-7. doi: 10.1002/mds.25111. Epub 2012 Jul 13.

C9ORF72 expansion in amyotrophic lateral sclerosis/frontotemporal dementia also causes parkinsonism

O'Dowd S, Curtin D, Waite AJ, Roberts K, Pender N, Reid V, O'Connell M, Williams NM, Morris HR, Traynor BJ, Lynch T.

Mov Disord. 2012 Jul;27(8):1072-4. doi: 10.1002/mds.25022.

Association between Parkinson's disease and the HLA-DRB1 locus

Ahmed I, Tamouza R, Delord M, Krishnamoorthy R, Tzourio C, Mulot C, Nacfer M, Lambert JC, Beaune P, Laurent-Puig P, Loriot MA, Charron D, Elbaz A.

Mov Disord. 2012 Aug;27(9):1104-10. doi: 10.1002/mds.25035. Epub 2012 Jul 13.

Functional brain imaging of cognitive dysfunction in Parkinson's disease

Hirano S, Shinotoh H, Eidelberg D.

J Neurol Neurosurg Psychiatry. 2012 Oct;83(10):963-9. doi: 10.1136/jnnp-2011-301818. Epub 2012 Jul 17.

LRRK2 A419V is not associated with Parkinson's disease in different Chinese populations

Wu YR, Tan LC, Fu X, Chen CM, Au WL, Chen L, Chen YC, Prakash KM, Zheng Y, Lee-Chen GJ, Zhao Y, Zeng JS, Tan EK, Pei Z.

PLoS One. 2012;7(7):e36123. doi: 10.1371/journal.pone.0036123. Epub 2012 Jul 10.

Impact of community pharmaceutical care on patient health and quality of drug treatment in Parkinson's disease

Schröder S, Martus P, Odin P, Schaefer M.

Int J Clin Pharm. 2012 Oct;34(5):746-56. doi: 10.1007/s11096-012-9672-9. Epub 2012 Jul 19.

Therapeutic approach to neurodegenerative diseases by medical gases: focusing on redox signaling and related antioxidant enzymes

Fujita K, Yamafuji M, Nakabeppu Y, Noda M.

Oxid Med Cell Longev. 2012;2012:324256. doi: 10.1155/2012/324256. Epub 2012 Jul 1.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias